>
Switch to:

Allergy Therapeutics ROC %

: -61.87% (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Allergy Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Jun. 2021 was -61.87%.

As of today (2021-12-07), Allergy Therapeutics's WACC % is 9.76%. Allergy Therapeutics's ROC % is 7.89% (calculated using TTM income statement data). Allergy Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Allergy Therapeutics ROC % Historical Data

The historical data trend for Allergy Therapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
ROC %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.68 -24.84 10.71 18.65 7.98

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
ROC % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.88 89.27 -40.82 79.47 -61.87

Allergy Therapeutics ROC % Calculation

Allergy Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2021 is calculated as:

ROC % (A: Jun. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2020 ) + Invested Capital (A: Jun. 2021 ))/ count )
=5.6535764375877 * ( 1 - 21.08% )/( (53.257822277847 + 58.604488078541)/ 2 )
=4.4618025245442/55.931155178194
=7.98 %

where

Invested Capital(A: Jun. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=107.91614518148 - 8.4217772215269 - ( 46.260325406758 - max(0, 22.812265331665 - 69.048811013767+46.260325406758))
=53.257822277847

Invested Capital(A: Jun. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=123.54698457223 - 9.3632538569425 - ( 56.483870967742 - max(0, 25.568022440393 - 81.147265077139+56.483870967742))
=58.604488078541

Allergy Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2021 is calculated as:

ROC % (Q: Jun. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2020 ) + Invested Capital (Q: Jun. 2021 ))/ count )
=-32.953716690042 * ( 1 - -1.15% )/( (49.14247311828 + 58.604488078541)/ 2 )
=-33.332684431978/53.87348059841
=-61.87 %

where

Invested Capital(Q: Dec. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=133.0685483871 - 19.021505376344 - ( 64.904569892473 - max(0, 21.978494623656 - 92.950268817204+64.904569892473))
=49.14247311828

Invested Capital(Q: Jun. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=123.54698457223 - 9.3632538569425 - ( 56.483870967742 - max(0, 25.568022440393 - 81.147265077139+56.483870967742))
=58.604488078541

Note: The Operating Income data used here is two times the semi-annual (Jun. 2021) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Allergy Therapeutics's WACC % is 9.76%. Allergy Therapeutics's ROC % is 7.89% (calculated using TTM income statement data). Allergy Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Allergy Therapeutics ROC % Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)